Liraglutide Has Two FDA-Approved Generics. Here Is Why It Is Still Not the Obvious Choice
Liraglutide is the only GLP-1 with FDA-approved generics on the US market: one referencing Victoza approved in December 2024, one referencing Saxenda in August 2025. That makes it the cheapest approved route. It is also a daily injection that produced roughly 6.4% mean weight loss against semaglutide's 15.8% in the only trial comparing them directly.
What STEP-8 found
| Arm | Mean weight loss | Dosing |
|---|---|---|
| Semaglutide 2.4 mg | ~15.8% | Once weekly |
| Liraglutide 3.0 mg | ~6.4% | Once daily |
| Placebo | ~1.9% | — |
Roughly two and a half times the weight loss, on a seventh of the injections. Open-label, and smaller than the main STEP trials.
Where the three molecules sit
Shown as tenths of a percent: 225 = 22.5%. Separate trials with different populations, except the two STEP-8 arms, which are a direct comparison.
Why a generic exists here and nowhere else
Liraglutide's patents expired earlier, and it is a peptide that follows the ANDA generic pathway rather than the biosimilar route. Semaglutide's compound patent runs to at least 2032 in the United States, with method-of-use, device and formulation patents alongside it. Tirzepatide is further out again.
So the presence of a generic here is a fact about patent timing, not about which drug works best. The two are unrelated, and conflating them is the most common error in coverage of this topic.
The adherence question no efficacy figure captures
Seven injections a week against one. Trials measure what happens under trial conditions, with reminders and follow-up. Daily dosing in ordinary life is a different proposition, and discontinuation was higher on liraglutide than semaglutide in the reported analysis.
If cost is genuinely the binding constraint, generic liraglutide is a legitimate approved option worth raising with a prescriber. It should be raised knowing the effect size and the dosing burden, not as a cheaper version of the same treatment.
What a generic actually guarantees
An approved generic is not "similar". It has demonstrated bioequivalence to the reference product and contains the same active ingredient in the same amount by the same route. That is a regulatory standard with data behind it.
This is the distinction that matters when the word "generic" is used loosely in GLP-1 marketing. A compounded preparation is not a generic: no bioequivalence demonstration, no ANDA, no reference-product comparison. The two words describe entirely different things and are used interchangeably constantly.
| Approved generic | Compounded preparation | Grey-market import | |
|---|---|---|---|
| Bioequivalence demonstrated | Yes | No | No |
| FDA application reviewed | Yes, ANDA | No | No |
| Same active ingredient guaranteed | Yes | Ask — salt forms differ | Unknown |
| Legal to sell in the US | Yes | With patient-specific justification | No |
| Exists for liraglutide | Yes, two | — | — |
| Exists for semaglutide | No, not before 2032 | Yes, narrowed | — |
The first column is the only one where 'generic' is accurate.
When generic liraglutide is genuinely the right answer
- Cost is the binding constraint and the alternative is no treatment.
- You need an approved product and cannot access semaglutide or tirzepatide.
- Daily injection is acceptable to you in practice, not just in principle.
- A smaller expected effect is acceptable — around 6.4% in the head-to-head against 15.8%.
What this page does not settle
- Actual pharmacy pricing. Generic prices vary by pharmacy and change frequently.
- Whether it will work for you. STEP-8 reported a mean; individual results vary widely.
- Whether a semaglutide generic will follow. Not in the US before 2032 on current patent expectations.
What the arrival of generics tells you about the next five years
Liraglutide is a preview of the semaglutide patent cliff, and it is instructive in a way most coverage misses: the generic arrived after the molecule had already been superseded clinically. By the time cheap liraglutide was available, semaglutide and tirzepatide had delivered two and three times the effect.
The same sequence is plausible for semaglutide. A US generic is not expected before 2032, by which time whatever is in phase 3 today will have reported. Cheap access to a 2018 molecule in 2032 is a real benefit for people who need an affordable option, and it is not the same as cheap access to the best available treatment.
| Molecule | Mean weight loss | Approved generic in the US |
|---|---|---|
| Liraglutide | ~6.4% (STEP-8 arm) | Yes — Dec 2024 and Aug 2025 |
| Semaglutide | 14.9% (STEP-1) | Not before 2032 |
| Tirzepatide | 22.5% (SURMOUNT-1) | Later still |
The cheapest approved option is consistently the least effective one, and that is a predictable consequence of how patents expire.
What this page does not settle
- Generic pricing at your pharmacy. It varies and changes frequently.
- Whether liraglutide is right for you. A prescriber weighs effect size, dosing burden and cost together.
- Whether the pattern repeats. Patent timing and clinical development are independent, and this alignment is a coincidence of scheduling rather than a rule.
Common questions
Is generic liraglutide the same as Saxenda?
An approved generic has demonstrated bioequivalence to its reference product and contains the same active ingredient in the same amount by the same route. That is a regulatory standard supported by data, and it is a substantially stronger guarantee than the word "generic" carries in ordinary speech.
Why has nobody made generic Ozempic?
Patents. Semaglutide's compound patent runs to at least 2032 in the United States, with method-of-use, device and formulation patents alongside it. More than a dozen companies have signalled interest to the FDA, and the first to file wins 180 days of exclusivity — which is why development is running years ahead of the expiry.
Should I switch to liraglutide to save money?
That is a prescriber's conversation, and the trade is explicit rather than hidden: a smaller expected effect, around 6.4% against 15.8% in the only direct comparison, and seven injections a week instead of one. If the alternative is no treatment because of cost, it is a legitimate approved option worth raising.
Are there generics for tirzepatide?
No, and they are further out than semaglutide's. Compounded preparations are not generics: no bioequivalence demonstration, no application reviewed, no reference-product comparison.